Rizatriptan Benzoate Tablet, Orally Disintegrating
Product Images NDC 51407-680

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 51407-680). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-679-03cb (pl).jpg (51407 679 03cb (pl))

Packaging label for Rizatriptan Benzoate orally disintegrating tablets USP 5 mg, showing a blister card of 3 tablets. The label includes dosage strength, manufacturer Golden State Medical Supply, Inc., and drug facts such as the amount of active ingredient per tablet and storage instructions. The label also indicates the product is Rx only, child-resistant packaging, and includes barcode and lot information areas.*

FDA Label Image

51407-680-03cb (pl).jpg (51407 680 03cb (pl))

Packaging label for Rizatriptan Benzoate 10 mg orally disintegrating tablets USP by Golden State Medical Supply, Inc. The label indicates 3 tablets (1 blister card of 3 tablets), marketed by GSMS, Incorporated, Camarillo, CA, Made in India. It includes storage instructions, phenylalanine warning, barcode, and a child-resistant unit-of-use package statement.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A Kaplan-Meier plot showing the estimated probability over time (hours post-dose up to 2 hours) of achieving an initial headache response with Rizatriptan Benzoate Tablets at 5 mg and 10 mg doses compared to placebo. The plot uses different markers for placebo, 5 mg, and 10 mg tablets, with response probability increasing over time for treatment groups.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In P (Rizatriptan Fig2)

A Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets (5 mg and 10 mg) or placebo for migraines over 24 hours following the initial dose. The vertical axis represents the estimated probability of remediation or rescue, and the horizontal axis shows hours post-dose up to 24 hours. The graph compares placebo, 5 mg, and 10 mg doses from pooled clinical studies.*

FDA Label Image

Figure 3: Estimated Probability Of Achieving An Initial Headache Response With Rizatriptan Benzoate Orally Disintegrating Tablets By 2 Hours In Pooled Studies 5 And 6‡ (Rizatriptan Fig3)

A Kaplan-Meier plot showing the estimated probability of achieving an initial headache response within 2 hours after dosing with Rizatriptan Benzoate orally disintegrating tablets at 5 mg and 10 mg strengths compared to placebo. The graph displays time post-dose on the x-axis and estimated probability of response on the y-axis, with increasing response probabilities for both doses over 2 hours, higher than placebo.*

FDA Label Image

Figure 4: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Orally Disintegrating Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of (Rizatriptan Fig4)

A Kaplan-Meier curve chart depicting the estimated probability over 24 hours that patients take a second dose of Rizatriptan Benzoate orally disintegrating tablets (5 mg and 10 mg) or placebo for migraine treatment. The x-axis represents hours post-dose, and the y-axis shows the estimated probability of rescue medication use.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig5)

A line graph depicting the observed percentage of patients reporting no headache pain by 2 hours post-dose in Study 7. The graph compares Rizatriptan Benzoate orally disintegrating tablets to a placebo, showing percentage on the y-axis and hours post second dose on the x-axis. Rizatriptan shows a higher percentage of patients pain-free over time compared to placebo.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure of Rizatriptan Benzoate showing the molecular arrangement of its active ingredient, including the triazole, indole, and benzoate groups as depicted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.